{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:59:21Z","timestamp":1790035161497,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T09:28:30Z","timestamp":1679390910000},"page":"2734-2738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["What\u2019s in a number? The value of titers as routine proof of immunity for medical students"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9129-5136","authenticated-orcid":false,"given":"Carmen L.","family":"Charlton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley-Nicole M.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Alexa","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil N.","family":"Kanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie C.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.009_b0005","unstructured":"Canadian Immunization Guide. Public Health Agency of Canada. 2021 URL: https:\/\/www.canada.ca\/en\/public-health\/services\/canadian-immunization-guide.html Accessed October 14, 2022."},{"key":"10.1016\/j.vaccine.2023.03.009_b0010","doi-asserted-by":"crossref","unstructured":"Measles outbreaks: what does it represent for the elimination strategy in the region of the Americas? A call for the action. M. L. Avila-Aguero, K. Camacho-Badilla and R. Ulloa-Gutierrez. Expert review of vaccines 2015 Vol. 14(8): 1043. DOI:10.1586\/14760584.2015.1055325.","DOI":"10.1586\/14760584.2015.1055325"},{"key":"10.1016\/j.vaccine.2023.03.009_b0015","unstructured":"Nationwide rubella epidemic--Japan, 2013. Centers for Disease Control and Prevention (CDC). Morb Mortal Wkly Rep 2013 Vol. 62(23): 457-62. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23760185."},{"key":"10.1016\/j.vaccine.2023.03.009_b0020","unstructured":"ACIP vaccine recommendations and guidelines. Advisory Committee on Immunization Practices. 2013. URL: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/index.html Accessed October 12, 2022."},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.009_b0025","first-page":"e00269","article-title":"Calibration and Evaluation of Quantitative Antibody Titers for Measles Virus by Using the BioPlex 2200","volume":"24","author":"Hatchett","year":"2017","journal-title":"Clin Vaccine Immunology"},{"key":"10.1016\/j.vaccine.2023.03.009_b0030","doi-asserted-by":"crossref","unstructured":"Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination B. J. Cohen,D. Doblas,N. Andrews. Vaccine. 2008. Vol. 26(50):6392-6397. DOI: 10.1016\/j.vaccine.2008.08.074.","DOI":"10.1016\/j.vaccine.2008.08.074"},{"issue":"3","key":"10.1016\/j.vaccine.2023.03.009_b0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CVI.00621-13","article-title":"Estimates of Mumps Seroprevalence May Be Influenced by Antibody Specificity and Serologic Method","volume":"21","author":"Latner","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.03.009_b0040","doi-asserted-by":"crossref","unstructured":"A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults. P. Kaaijk, A.J. Wijmenga-Monsuur, M. A. van Houten MA, I. K. Veldhuijzen, H. I. Ten Hulscher, J. Kerkhof, F. R. van der Klis, R. S. van Binnendijk. J Infect Dis. 2020. Vol. 221:902-909. DOI: 10.1093\/infdis\/jiz188.","DOI":"10.1093\/infdis\/jiz188"},{"key":"10.1016\/j.vaccine.2023.03.009_b0045","doi-asserted-by":"crossref","unstructured":"Clinical characteristics of measles in previously vaccinated and unvaccinated patients in California. Cherry JD, Zahn M. Clin Inf Dis 2018; Vol. 67:1315-1319.","DOI":"10.1093\/cid\/ciy286"},{"issue":"4","key":"10.1016\/j.vaccine.2023.03.009_b0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.vaccine.2016.12.014","article-title":"The economic impact of prenatal varicella immunity among pregnant women in Alberta","volume":"35","author":"Passi","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2023.03.009_b0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.vaccine.2014.12.022","article-title":"Determining rubella immunity in pregnant Alberta women 2009\u20132012","volume":"33","author":"Lai","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.009_b0060","doi-asserted-by":"crossref","unstructured":"Emergence of Attenuated Measles Illness Among IgG-positive\/IgM-negative Measles Cases: Victoria, Australia, 2008-2017. K. B. Gibney, L. O. Attwood, S. Nicholson, T. Tran, J. Druce, J. Healy, J. Strachan, L. Franklin, R. Hall, G. B. Cross. Clin Infect Dis. 2020. Vol. 70:1060-1067. DOI: 10.1093\/cid\/ciz363.","DOI":"10.1093\/cid\/ciz363"},{"key":"10.1016\/j.vaccine.2023.03.009_b0065","doi-asserted-by":"crossref","unstructured":"Measles Outbreak Among Previously Immunized Healthcare Workers, the Netherlands. Hahn\u00e9 SJ, Nic Lochlainn LM, van Burgel ND, Kerkhof J, Sane J, Yap KB, et al. J Infect Dis 2014; Vol. 214:1980-1986. DOI: 10.1093\/infdis\/jiw480.","DOI":"10.1093\/infdis\/jiw480"},{"key":"10.1016\/j.vaccine.2023.03.009_b0070","doi-asserted-by":"crossref","unstructured":"Measles outbreak in a tertiary level hospital, Porto, Portugal, 2018: challenges in the post-elimination era. R. S\u00e1 Machado, M. Perez Duque, S. Almeida, I. Cruz, A. Sottomayor, I. Almeida, J. R. Oliveira, D. Antunes. 2018. Euro Surveill. Vol. 23:18-00224. DOI:10.2807\/1560-7917.ES.2018.23.20.18-00224","DOI":"10.2807\/1560-7917.ES.2018.23.20.18-00224"},{"issue":"5","key":"10.1016\/j.vaccine.2023.03.009_b0075","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/infdis\/jiz508","article-title":"Long-term immunogenicity of measles vaccine: an Italian Retrospective Cohort Study","volume":"221","author":"Bianchi","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.009_b0080","first-page":"21:475","volume":"Vol","author":"Bianchi","year":"2021","journal-title":"Long -term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study"},{"key":"10.1016\/j.vaccine.2023.03.009_b0085","unstructured":"Chickenpox (Varicella). Centers for Disease Control. 2021. URL: https:\/\/www.cdc.gov\/chickenpox\/lab-testing\/lab-tests.html Access date: October 14, 2022."},{"key":"10.1016\/j.vaccine.2023.03.009_b0090","doi-asserted-by":"crossref","first-page":"e00265","DOI":"10.1128\/JCM.00265-20","article-title":"Qualitative Variation among Commercial Immunoassays for Detection of Measles-Specific IgG","volume":"Vol. 58","author":"Latner","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2023.03.009_b0095","unstructured":"Immunization of workers: Canadian Immunization Guide. Public Health Agency of Canada. 2022. URL: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-3-vaccination-specific-populations\/page-11-immunization-workers.html#p3c10a2. Accessed October 14, 2022."},{"key":"10.1016\/j.vaccine.2023.03.009_b0100","unstructured":"Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2011. 60(RR07):1-45. URL: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6007a1.htm. Accessed October 14, 2022."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:01Z","timestamp":1759404301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X23002566"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What\u2019s in a number? The value of titers as routine proof of immunity for medical students","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}